Santa Clara University

Scholar Commons
Bioengineering Senior Theses

Engineering Senior Theses

Spring 2018

Engineering Synthetic Antibody for Prostate
Cancer Detection
Kimberley Gonzalez
Santa Clara University, kgonzalez@scu.edu

Tatum Prosswimmer
Santa Clara University, tprosswimmer@scu.edu

Cassandra Stawicki
Santa Clara University, cstawicki@scu.edu

Follow this and additional works at: https://scholarcommons.scu.edu/bioe_senior
Part of the Biomedical Engineering and Bioengineering Commons
Recommended Citation
Gonzalez, Kimberley; Prosswimmer, Tatum; and Stawicki, Cassandra, "Engineering Synthetic Antibody for Prostate Cancer
Detection" (2018). Bioengineering Senior Theses. 75.
https://scholarcommons.scu.edu/bioe_senior/75

This Thesis is brought to you for free and open access by the Engineering Senior Theses at Scholar Commons. It has been accepted for inclusion in
Bioengineering Senior Theses by an authorized administrator of Scholar Commons. For more information, please contact rscroggin@scu.edu.

ENGINEERING SYNTHETIC ANTIBODY FOR
PROSTATE CANCER DETECTION

By
Kimberley Gonzalez, Tatum Prosswimmer, Cassandra Stawicki

SENIOR DESIGN PROJECT REPORT

Submitted to
The Department of Bioengineering
of
SANTA CLARA UNIVERSITY

In Partial Fulfillment of the Requirements
for the degree of
Bachelor of Science in Bioengineering

Santa Clara, California
Spring 2018

1

ENGINEERING SYNTHETIC ANTIBODY FOR
PROSTATE CANCER DETECTION
Kimberley Gonzalez, Tatum Prosswimmer, Cassandra Stawicki

Department of Bioengineering
Santa Clara University
2018

Abstract
This Senior Design project seeks to manufacture an E. Coli based antibody for prostate
cancer detection using unnatural amino acid incorporation. Current diagnostic techniques
take advantage of the high binding specificity of monoclonal antibodies to detect the
concentration of prostate specific antigen (PSA) in a blood sample. Production of this
technology is lengthy and costly, while simultaneously incurring countless ethical problems
related to animal welfare and accessibility. This project proposes a synthetic antibody that
can be produced efficiently in single E. Coli cells and exhibits complementary binding to
PSA. By incorporating an unnatural amino acid into a recombinant peptide sequence, binding
affinity between substrate and antibody is substantially increased, effectively expanding the
genetic code by introducing a novel function. Expression of the antibody is followed by
extraction and purification of the synthetic antibody from cellular debris. Finally, the
antibody’s binding strength and specificity to PSA is tested with respect to the monoclonal
antibody with complementary binding to PSA. Assuming the synthetic antibody has greater
or equivalent binding affinity than the currently used protein, this project will replace
ethically questionable diagnostic techniques with a cheaper alternative.
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Introduction
Background, Significance, and Motivation
Antibodies are natural glycoproteins produced by the immune system that neutralize or
eliminate foreign invader molecules and organisms. Due to high affinity, specificity, and
strength in binding to a specific antigen, antibodies enable immune cells to locate and
terminate target cells. This binding capacity has resulted in the commercialized use of
antibodies for a variety of research and medical practices, including qualitative and
quantitative analyses, and mediating or modulating physiological effects. Diagnostic
applications include Western Blotting, used to increase the sensitivity of an assay system,
and ELISA, used to analyze soluble antigens.1 In these processes, antibodies are manipulated
to detect the presence of specific proteins, antibodies, or antigens in a sample. Therapeutic
antibodies are currently used to treat asthma, autoimmune disorders, and cancers, but have
also been tested for treatment of infectious diseases.1

Among a myriad of therapeutic and diagnostic applications is the detection of prostate cancer
using monoclonal antibodies. Prostate cancer is the most common form of cancer among
white, black, asian, and hispanic men, the second most common among American
Indian/Alaska Native men, and the second leading cause of cancer death among white, black,
American Indian/Alaska Native, and Hispanic men.2
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Figure 1. Overview of prostate cancer statistics

One in nine men will be diagnosed with prostate cancer within his lifetime, while one in
forty-one men will die from it.3 Early detection is crucial: the relative 5-year survival rate for
the “local stage” in which the disease is contained within the prostate is nearly 100%.
Meanwhile, survival is only about 29% for the “distant stage”, which includes stage IV
cancers.4

Figure 2. Diagnosis statistics. Distribution of prostate cancer diagnosis stages and relative survival rates 5
years post-diagnosis4
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Detection is done either through a digital rectal exam or by measuring the concentration of
PSA in the blood.4 In the rectal exam, the prostate is assessed for enlarged or abnormal
physiology. In the blood panel, the level of PSA in the blood is detected using a monoclonal
antibody. As shown in Figure 1, a healthy prostate secretes a relatively small concentration of
PSA, part of which is taken up into the bloodstream. However, in those with prostate cancer,
an elevated level of PSA is secreted and absorbed into the blood.4

Figure 3. Healthy versus disease state related PSA levels. Comparison of PSA release from a healthy prostate
and a prostate with cancer, as well as uptake into the bloodstream.

Monoclonal antibodies currently dominate both the research and medical spheres for
countless diseases, including prostate cancer. Despite their unique specificity and uniformity,
the use of monoclonal antibodies raises ethical concerns, presents high contamination risks,
and requires a lengthy and expensive production process due to the sheer complexity of the
molecule. While many of these challenges can be overcome by using multiple monoclonal
antibodies, this route is difficult, expensive, and time consuming.5

Thus, there is a need for a similarly selective molecule which can be engineered to target
specific antigens, without incurring these ethical, social, and economic challenges. Unnatural
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amino acid incorporation is a promising new technology which will expand the genetic code
and introduce novel functions into the biological world. By incorporating a non-biologically
relevant amino acid into a recombinant peptide sequence, a “synthetic antibody” can be
engineered with specific binding capabilities; and, by designing a synthetic antibody which
can be produced in E. Coli, there is potential to circumvent the many disadvantages incurred
through the traditional monoclonal antibody model.

Literature Review
Unnatural Amino Acid Incorporation
Unnatural amino acids contain functional groups that are uncommon to the 20 known
biological amino acids. Bioengineers Wals and Ovaa have explored the various applications
of unnatural amino acid incorporation through a mutated tRNA synthetase, allowing
engineers to introduce novel function in proteins by taking advantage of the inherent
relationship between protein structure and function.6 Unnatural amino acid incorporation
allows selective modification that can be used for therapeutic applications.

Design
A paper by Umeda et al. explores the possible applications of unnatural amino acid
incorporation, such as for protein detection probes or therapeutic purposes.7 The proposed
design of the experimental synthetic antibody is partially derived from that of Umeda et al.
paper. Their system describes the incorporation of an unnatural amino acid,
3,4-dihydroxy-L-phenylalanine (L-DOPA), to a peptide (TOP1), GFP reporter protein, and a
6-His purification tag. This project proposes a similar design, but includes a genetically
engineered sequence specific for PSA, thus pioneering the use of unnatural amino acids for
prostate cancer detection.
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Specifically, this design replaces the TOP1 peptide used by Umeda et. al with the
PSA-specific sequence; however, the principles of unnatural amino acid incorporation are
generally the same as those outlined in the referenced literature.

Figure 4. Synthetic antibody binding PSA. Design of the synthetic antibody includes 15 amino acid peptide
sequence (orange), unnatural amino acid (L-DOPA, black), green fluorescent protein (green), and 6-His
purification tag (blue). The addition of sodium periodate triggers the formation of a covalent bond (red) between
the antibody and PSA (purple).

Critiques of Current Literature and Technologies
Monoclonal antibodies
Monoclonal antibodies are often used by researchers as drug targets and diagnostic tools
because they can be used in most every stage when researching protein targets and
characterization. However, the production of monoclonal antibodies incurs questionably
ethical practices. To avoid jeopardizing human safety, production of monoclonal antibodies
is done in animals, typically mice, using the hybridoma model. The hybridoma model
involves injecting live animals which disease agents in order to induce an immune response,
leading to antibody synthesis. The antibodies are then extracted through an extensive process
which often causes excessive distress in the animal.8 These practices present a clear need for
a diagnostic and therapeutic replacement.
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Polyclonal antibodies
One potential alternative is polyclonal antibodies, which uphold identical structure and
specificity as the monoclonal counterpart, while requiring less time for production at a
significantly lower cost. However, they maintain the same ethical pitfalls as monoclonal
antibodies because they must also be produced in animals. Also, there is batch to batch
variability in polyclonal antibody production, as well as potential for cross reactivity because
the antibodies are able to recognize multiple epitopes, unlike monoclonal antibodies.1

Aptamers
Aptamers have also been considered as another potential alternative to monoclonal
antibodies. They are short molecules of either RNA or single-stranded DNA that are capable
of folding into 3-D conformations which can bind specific target proteins. Aptamers are
much smaller than monoclonal antibodies and can be synthesized by simpler chemical
mechanisms, but they are not a viable alternative to monoclonal antibodies because they lack
stability over ranges of temperature and pH, and in the presence of commonly used buffers.9

Protein scaffolds
Protein scaffolds are formed from fragmented polypeptides and can also demonstrate
similarly specific binding to target molecules. However, similarly to aptamers, protein
scaffolds are not able to maintain a stable structure over a range of conditions. They also lack
common functional modifications exhibited by monoclonal antibodies, such as disulfide
bonding.10

Project Objectives
The goal of this project is to engineer a synthetic antibody for prostate cancer detection as a
cost-effective and ethically sourced diagnostic alternative to monoclonal antibodies. Because
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preliminary cloning and sequencing of the plasmid is complete, this project will focus on the
production and testing of the synthetic antibody.

Toxicity screening must be done first in order to ensure that proper expression of the
engineered plasmid in E. Coli is possible with the additional synthetic components. Next, the
synthetic antibody is isolated through a protein purification method known as manual affinity
chromatography. Finally, the protein will be analyzed for binding affinity, specificity, and
selectivity toward PSA and statistically compared to mAb. This validation step is crucial to
proving viability of the proposed synthetic antibody as an ethical and effective replacement
of mAb; the former must have equivalent, or greater, diagnostic capabilities as the previously
established standard method in order to be considered as a possible replacement.

This project focuses on the incorporation of an unnatural amino acid into a peptide which
specifically codes for PSA binding. This amino acid and the PSA specific sequence are not
part of the bacteria’s biological code; thus, this molecule is considered a synthetic antibody.
Because this system is produced in E. Coli and has potential to assist in prostate cancer
detection, it serves as a model for the development of additional synthetic antibodies which
may replace monoclonal antibodies as the gold standard in detection. This model will
hopefully be able to overcome the challenges of mAb discussed previously as it will incur
fewer costs, shorter production times, and greater scalability, while maintaining comparable
functionality.

Overall Design
A synthetic antibody manufactured in E. Coli presents three main advantages which
overcome the challenges associated with monoclonal antibody use and production. The
proposed synthetic antibody will be more cost efficient than the monoclonal antibody
counterpart, be ethically produced, and will contain no batch to batch variability between
samples. There are four main components to the design of the antibody: a ‘P2’ peptide
15

sequence which is complementary to the PSA sequence, the replication machinery necessary
for unnatural amino acid incorporation of L-DOPA, a GFP reporter protein, and a 6-His
purification tag.

Peptide Sequence
The P2 peptide sequence was computationally designed by Jon Henry Therriault and Thomas
Evans using an open source software called Chimera.11 The peptide sequence was screened
against anti-PSA monoclonal antibodies to have high binding affinity (3.5 μM) and
specificity to PSA.12

L-DOPA Incorporation
The second component of the synthetic antibody is an unnatural amino acid called
3,4-dihydroxy-L-phenylalanine (L-DOPA). L-DOPA is a derivative of tyrosine and it has
been demonstrated that it can be incorporated in recombinant proteins in E. Coli by
suppressing the amber stop codon, which has the codon sequence TAG.7 The unnatural
amino acid is able to form a stable covalent bond with a protein of choice, in this case PSA,
upon exposure to NaIO4.7 The L-DOPA is incorporated with a mutant tRNA and tRNA
synthetase, which are present in the engineered plasmids, in order to have successful
incorporation of the amino acid.11

GFP Reporter/Payload
Additionally, a GFP reporter protein is included in the gene sequence to visualize expression
of the synthetic antibody using UV light. This method of visualization and validation is
straightforward, simple to use, and a reliable, commonly used method to determine whether
the transformation and expression are successful.
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Purification Tag
Finally, a sequence of 6 consecutive histidines is placed in the gene sequence to aid in
protein purification. The 6-His tag is used to facilitate the protein purification by using
immobilized metal-affinity chromatography.13 Histidine has previously been established as
the amino acid with the most efficient retainment to the chromatography matrices.13
Plasmid Overview
In total there are two plasmids that are transformed into the E. Coli competent cells:
pAC-DHPheRS-6TRN plasmid and pET28b plasmid. The first plasmid has the L-DOPA
unnatural amino acid production sequence, including the mutant tRNA and tRNA synthetase,
and a Tet resistance gene. The second plasmid contains the GFP, 6-His tag, the P2 peptide
sequence, and a Kan resistance gene. The resistance genes are used as a verification for
successful transformation of both plasmids into the E. Coli cells, which will be discussed
further in the following sections.11

Milestones and Expected Results
The two plasmids were successfully designed, cloned, and transformed into E. Coli
competent cells by a previous senior design team.11 The first milestone of this project is to
successfully express the synthetic antibody in E. Coli cells. Here, different growth conditions
will need to be tested in order to optimize an adequate environment in which the cells will
not recognize the unnatural amino acid as a foreign entity and commence an apoptotic
sequence.

Once the expression is successful, the next step is to purify the protein from the E. Coli. The
purification must be done multiple times using the gold standard of monoclonal antibody
purification as a representative model. The process will need to highly effective and
optimized to its highest potential in order to ensure the greatest level of purity.
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The final step, once the expression and purification of the synthetic antibody is complete, is
to test the binding capabilities of the engineered synthetic antibody. In order to prove the
advantage of using a synthetic antibody over a monoclonal antibody, it must be tested for
binding strength, specificity, and sensitivity for PSA. The standards for the anti-PSA
monoclonal antibody are already well established and can be used as benchmark
measurements for the synthetic antibody.

Team Management
To ensure continuous efficiency and culpability from each team member throughout the
project, responsibilities will be distributed throughout the team. Cassandra is the primary
liaison with the School of Engineering, manages the team finances, and ensures all deadlines
are met. Kimberley coordinates meeting and laboratory scheduling for the team and
facilitates communications with the advisor, Dr. Zhang. Tatum supervises all writing and
editing for assignments and presentations, as well as the final report.

Budget
Through funding granted from the School of Engineering, the project has a $1,500 budget for
the year. We have $300 allocated for ten reactions using TOP10 competent cells. A $400
budget for reagents including: buffers, media, our protein target, and monoclonal antibodies.
To ensure that no genetic mutations occurred within our E.coli production system, we have
$90 for DNA sequencing analysis of our 45 nucleotide synthetic antibody. For protein
purifications, we have $500 allocated to cover the cost of protein gels and purification beads.
Finally, we estimate our consumables to cost approximately $210, which will cover dialysis
cassettes, filters, petri dishes, pipette tips, and other items needed for laboratory research. We
do not anticipate any issues to arise within our budget as we have accounted for additional
runs of sequencing and reactions using competent cells.
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Timeline
During the Fall term, we initiated toxicity screening and E. Coli expression. However, due to
the anticipated challenges of cell survival associated with the mutant tRNA synthetase, our
toxicity screening will run into the next term as we attempt to narrow in on the ideal
conditions to avoid cytotoxic responses. Additionally, within the Winter term, we will be
running the protein purifications and validation screening. Finally, during the Spring term,
we plan to finalize our results with quantitative analysis and any needed troubleshooting. We
do not anticipate any major setbacks or challenges beyond the toxicity screening phase.
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Chapter 1: Protein Expression
Introduction
The proposed synthetic antibody has been designed to make use of the highly conserved lac
operon. In a biological system, the complexly regulated lac operon stimulates lactose
metabolism. Because it is among the most well-understood operons, protein engineering
techniques often make use of it to produce recombinant proteins. Production of the L-DOPA
incorporated synthetic antibody in E. Coli first requires design of a plasmid which contains
the desired sequence within the lac operon transcription region. By mimicking the biological
system’s promoter and repressor functions, expression of the desired sequence can be easily
regulated. In this way, production of the proposed synthetic antibody can be closely
controlled.

Figure 5. Induction of lac operon with IPTG. Release of inhibitor from operator site using IPTG, instead of
allolactose, to induce transcription.
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Back-up Plan
Although expression protocols are well established and documented, it is not a simple task to
accomplish using unnatural amino acids and mutant translation machinery. The main concern
at this critical step is the lack of E. Coli growth. In order to ensure optimal growth, multiple
carbon sources including glycerol and glucose will be introduced at varying concentrations to
optimize cell growth.

Materials and Methods
Plasmid Validation
The first step in this project is to validate that the experimental plasmids have been properly
transformed into the E. Coli competent cells by plating the cells with specific antibiotics. The
pAC-DHPheRS-6TRN plasmid contains the mutant tRNA and tRNA synthetase needed for
unnatural amino acid incorporation as well as the tetracycline resistance gene. The
pET28b-P1+TAG+GFP+His contains an enhanced GFP reporter protein, the specific
sequence which will bind to PSA, a 6 Histidine purification tag, and kanamycin resistance
genes. Cells were plated on a variety of antibiotics to ensure that the plasmids were properly
transformed.

Antibiotic(s)

Growth?

Tetracycline

Yes

Kanamycin

Yes

Ampicillin

No

Tetracycline + Kanamycin

Yes

Table 1. Validation of plasmid transformation using antibiotic resistance genes.
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Because the cells did not grow in the negative control (ampicillin) but did grow when plated
with both conferred resistance genes, correct plasmid transformation into competent cells is
verified.

Figure 6. Plated TOP10 competent cells. Experimental cells containing plasmids
pAC-DHPheRS-6TRN and pET28 (left) and control cells (right).

Toxicity Response
The plated cells above show the differences in colony growth between the experimental and
control. The plated cells on the left contain both experimental plasmids, which include a
TAG codon sequence which signals for the addition of the unnatural amino acid, L-DOPA,
into the growing peptide sequence. The cells on the right contain a GCG codon sequence in
place of the TAG, which codes for an alanine amino acid residue. Because the control
contains only biologically relevant amino acids, there is no toxicity response evident in the
size and shape of the cell colonies. By comparing the colonies on both plates, it is evident by
the small and slightly misshapen colonies on the left that there is a toxicity response based on
the synthetic nature of the experimental peptide sequence. This indicates that an optimized
antibody expression protocol is necessary to ensure adequate cell growth and expression.
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Optimized Antibody Expression Protocol
The optimized antibody expression protocol was developed from a similar design described
in a paper by Umeda et. al. First, 500 microliters of glycerol stock containing the
experimental competent cells were added to 250 milliliters of M9 salts with 5% glucose as
the carbon source. Thirty and twenty-five micrograms per milliliter of Kanamycin and
Tetracycline, respectively, were subsequently added. This culture was grown in a dark
incubator at 37°C with agitation. Once an optimal OD600 is reached, 1 mM L-DOPA was
added for unnatural amino acid incorporation. Agitation at 37°C continues for 40 minutes, at
which point 1 mM IPTG is added. Once induction with IPTG begins, the temperature is
lowered to 30°C, and shaking continues for an additional six hours. Finally, the cultures are
viewed using a Transilluminator to visualize the fluorescence of both the experimental and
control.

Results

Figure 7. Expression visualization under UV light. Experimental cultures, with L-DOPA incorporation (1)
and no L-DOPA (2), measured under UV light after 6 hours of incubation
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Flasks 1 and 2 contain E. Coli competent cells transformed with the synthetic antibody
experimental plasmid. Flask 1 contains L-DOPA, which was added once the cells reached
OD600 of 0.4, while flask 2 does not contain L-DOPA. Both flasks 1 and 2 contain IPTG in
order to induce antibody expression. Green fluorescence indicates successful expression of
the synthetic antibody with unnatural amino acid incorporation due to the strategic placement
of GFP at the end of the experimental plasmid. As may not be clear in Figure 7, flask 1
fluoresces brighter than flask 2. This is to be expected because flask 1 contains the
experimental, and flask 2 the control.

Discussion
Plasmid Validation
The growth of colonies on both culture plates, each with Kanamycin and Tetracycline
antibiotics, demonstrated the successful transformation of both pAC-DHPheRS-6TRN
(containing a Tetracycline resistance gene) and pET28 (containing a Kanamycin resistance
gene) plasmids. The visible variation in colony size suggests that the cultures with TAG are
expressing an expected toxicity response. This toxicity response must be diligently addressed
during the antibody expression step.

Toxicity Response
Due to the toxicity response caused by mutant tRNA and tRNA synthetase, cell growth and
subsequent antibody expression proved challenging. Multiple expression protocols were
executed to determine which protocol would optimize cell growth and expression.

First, a traditional growth protocol was followed in which 500 microliters of glycerol stock
containing the competent cells of interest were grown in minimal media. Optimal growth was
expected after approximately 24 hours. However, after incubation for 72 hours, the cells
grew only to an OD600 of approximately 0.2; the desired OD600 reading is between 0.4-0.6.
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Next, a similar protocol was conducted in which an additional carbon source, glycogen, was
added to the culture during growth. Similar to the first protocol, optimal cell growth was not
reached, even after multiple executions and extended incubation.

Following approximately 10 weeks of troubleshooting, the optimal protein expression
protocol was reached. It was determined that adding glucose to the growth media, along with
M9 salts, effectively disguised the mutant tRNA and tRNA synthetase, preventing the cells
from signaling for apoptosis. Using this protocol, it was possible to grow the cells to optimal
concentration, following which the antibody could be expressed using induction with IPTG.
Thus, by adding an additional carbon source, glucose, the cells were able to bypass their
foreign invader response and grow to an optimal optical density.

Figure 8. Bacterial growth curves. Comparison between initial growth curve (without added carbon source),
the typical bacterial growth curve, and the growth curve following addition of glucose as a carbon source.
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As shown in Figure 8, adding glucose as an additional carbon source did not entirely combat
the toxicity response caused by the synthetic antibody. This can be determined by the fact
that the cell’s logarithmic growth phase ended prematurely, transitioning to the stationary
phase before reaching OD600 of 0.6, which is the typically desired optical density. However,
for the purposes of this project, an OD600 of 0.4 will suffice for subsequent antibody
expression. Thus, the protocol containing glucose as an additional carbon source was
determined to be the optimized protocol for cell growth and antibody expression.

Antibody Expression
The validation of a successful protein expression is the signature green illumination from
GFP. Based on Figure 7, the E. Coli cells were able to successfully synthesize and express
the synthetic antibody. The flask on the left has a high level of fluorescence, indicating that
the plasmids have been fully expressed and that the synthetic antibody is being produced.
The flask on the right does not contain L-DOPA, but still appears to fluorescence. However,
this is because all living cells emit baseline fluorescence, so this is not of concern. Thus,
from these figures, accurate transformation and expression is confirmed.
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Chapter 2: Protein Purification
Introduction
In order to quantify the binding affinity and activity of the synthetic antibody, the protein
must be extracted and purified. Immobilized Metal Affinity Chromatography (IMAC) will be
used to purify the protein by taking advantage of the 6-His tag incorporated into the synthetic
antibody. This technique will allow the purification tag to bind to Nickel-charged
Nitrilotriacetic Acid (Ni-NTA) beads while other proteins are washed away. IMAC methods
are well-established and widely used as a method of protein purification.

Back-up Plan
In case the standard protocol is not successful, fast protein liquid chromatography, or FPLC,
will be used to purify the synthetic antibody. FPLC is an automated process which
incorporates a mobile phase and a stationary phase to separate proteins based on affinity.
Although this process is automated, it is typically used for large-scale purifications, and is
complicated to program. Thus, IMAC is the preferred method.

Materials and Methods
Lysate Step
Purification was conducted individually based on cell type and stock media. The pellet was
resuspended in 5 mL of lysis buffer, containing PBS, 1 mg/mL lysozyme, 0.5 mM PMSF,
and 10 mM imidazole. Suspension was transferred to a metal centrifuge tube and incubated
on ice for 20 minutes. The cells were sonicated at 30% alternating between 6 seconds on and
59 seconds off for 6 cycles. The lysate was then centrifuged at 4°C and 16,000 rpm for 40
minutes. 1 mL of the supernatant was stored at -20°C for gel analysis.
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During centrifugation of the lysate, 250 μL of HisPurTM Ni-NTA beads (Thermo Fisher
Scientific) were resuspended in 5 mL of wash buffer, containing PBS and 25 mM imidazole.
This was done for each culture with a volume ratio of 1:1000 for the volume of beads to
volume of initial culture. The suspension was centrifuged at 2,000 rpm for 4 minutes,
following which the supernatant was discarded. This process was repeated 3 additional times.

Flow-Through Step
Using the supernatant of the centrifuged lysate solutions, the Ni-NTA beads were again
resuspended. To allow the protein to bind to the 6-His tag specific beads, the suspension was
rocked at 4°C for 1 hour. Centrifugation was conducted at 4°C and 2,000 rpm for 4 minutes.
At the end, 1 mL of flow-through was saved and stored at -20°C.

Wash Step
The beads were then washed 5 times. In each wash, the beads were resuspended in wash
buffer, containing PBS and 25 mM imidazole, rocked for 20 minutes at 4°C, and centrifuged
at 4°C and 2,000 rpm for 4 minutes. After each wash, 1 mL of wash supernatant was stored
at -20°C for gel analysis, while the remainder was discarded.

Elution Step
The elution process was conducted twice, each time resuspending the beads in 200 μL of
elution buffer, containing PBS and 250 mM imidazole. The suspension was rocked for 20
minutes at 4°C, then centrifuged at at 4°C and 2,000 rpm for 4 minutes. After, supernatant
was extracted and stored at -20°C.
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Figure 9. Representation of protein purification stages. Diagram of competitive binding between imidazole
and 6-His tag to bind Ni-NTA beads

The eight stored samples (1 lysate, 1 flow-through, 5 wash steps, and 2 elutions) for each
purification conducted were analyzed using SDS-PAGE (GenScript) at 150 volts for 40
minutes. Visualization was done using Coomassie Brilliant Blue Dye to identify the location
of our protein throughout the purification and troubleshoot ways to keep our antibody in the
solution.
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Results

Figure 10a. Coomassie Brilliant Blue stained SDS-PAGE Gel. Gel visualization of eight samples from
protein purification washing and elution steps, with synthetic antibody band (circled in red) between 25-30kD.

Figure 10b. Chemiluminescence image of SDS-PAGE Gel. Gel visualization of eight samples and protein
ladder using chemiluminescence, with synthetic antibody band (circled in red) between 25-30kD.

Figures 10a and 10b show the results of the SDS-PAGE gel in both white light and
chemiluminescence. Wells 1-4 are from the protein expression of the synthetic antibody
while wells 6-9 are part of the control experiment that did not have L-DOPA. These wells
correspond to the samples that were stored during the purification process. As expected, there
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is no antibody in the wash steps because they are all bound to the Ni-NTA beads and it is
until the elution in well 4 where we see the band at 27kD. This band is due to the increase in
the imidazole concentration during elution which knocks the antibody off of the Ni-NTA and
into the supernatant.

Discussion
The imidazole in the various buffers competes with the 6-His tag on our antibody to bind to
the Ni-NTA beads due to the similarities in their molecular structure. The imidazole is bound
to the beads during the initial suspension and competes with the 6-His tag during the various
washes. The amount of imidazole added to the buffer solutions is inversely proportional to
the amount of protein that is bound to the Ni-NTA beads. We are able to keep our antibody
attached to the beads and wash out the impurities before we move on to the elution, which
knocks the antibody off the bead and allows us to harvest them from the supernatant. We
used native conditions to purify the synthetic antibody from the solution to keep the protein
intact through the purification step. In order to limit unspecific binding, we washed the beads
with wash buffer 5 times and eluted twice to unbind the synthetic antibody from the Ni-NTA
beads.

The predicted size of our antibody is 27kD and we were able to get a clear band between
25-30 kD (shown in red circle on Figure 10a and 10b). However, there are still other
molecules present in our elution which is evident from faint bands above and below our
target band. This is not an issue because the validation testing that will be conducted is
specific to the prostate specific antigen.
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Chapter 3: Validation Testing
Introduction
Validation testing is required to analyze the functionality of the synthetic antibody to ensure
it has equivalent or greater binding specificity and strength comparable to the current
standard measure of monoclonal antibodies. Our engineered synthetic antibody must be
tested to prove that proper incorporation of the unnatural amino acid is accomplished. To do
this, the Kd of both the experimental and control synthetic antibodies to PSA will be
measured using isothermal titration calorimetry (ITC). The Kd value will express the binding
affinity of the synthetic antibody to PSA.

The specificity and sensitivity of the engineered synthetic antibody to PSA is crucial to
establish a reliable system with both accuracy and precision. Each of these measures will be
tested with the use of Western Blot on titrated PSA samples to analyze the experimental
synthetic antibody compared to anti-PSA monoclonal antibodies.

Materials and Methods
Specificity Testing
In the first Western blot, the field will be divided into two sections (with PSA on both sides),
inserting the monoclonal antibody on the left and the synthetic antibody on the right. Both
are expected to bind to PSA, which will be visualized as a black band for the monoclonal
antibody and as a green band for the synthetic antibody carrying GFP. This confirms the
specific binding of the synthetic antibody to PSA.
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Sensitivity Testing
A second Western blot will be used to verify the sensitivity of the synthetic antibody in
comparison to the standard sensitivity of the monoclonal antibody. By adding an increased
concentration of the synthetic antibody to each successive well, the minimum concentration
of the synthetic antibody needed will be determined. Each successive well, beginning with
the well containing the minimum concentration for binding, will fluoresce green, indicating
the lowest concentration needed to bind PSA. Finding that the synthetic antibody has greater
sensitivity than the monoclonal antibody will confirm that this new detection method is a
successful replacement of the monoclonal antibody based diagnostic.

Discussion
It is expected that the binding strength of the experimental synthetic antibody will be
significantly greater than the control synthetic antibody since the L-DOPA, in the presence of
sodium periodate, triggers the formation of a covalent bond between the synthetic antibody
and PSA. Once the Kd values of the synthetic antibody are compared to the known binding
strength of the anti-PSA monoclonal antibodies, which is 1.1 ± 0.2 nM, the requirements of
binding affinity are satisfied. The experimental synthetic antibody needs to have at least a
comparable Kd in order to be a successful replacement technology for PSA detection.

Based on the current detection measures of PSA, normal conditions are considered to be
below 2.5 ng/mL, while concentrations of PSA between 2.5 ng/mL and 4.0 ng/mL are
indicative of prostate cancer. These ranges will be used as a standard in testing the
functionality of the synthetic antibody.
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Chapter 4: Conclusion
Summary
This project sought to engineer a synthetic antibody for prostate cancer detection using
unnatural amino acid incorporation. By circumventing the challenges incurred through the
use of monoclonal antibodies, this synthetic antibody presents a more efficient and
cost-effective method to detect prostate cancer. The use of E. Coli cells as replication
machinery also eliminates animal welfare concerns, as well as ensures there is no batch to
batch variability of the synthetic antibodies. Validation testing is currently underway, and
must be continued to validate that the designed antibody has equal or greater binding affinity
to PSA. Once verified that the synthetic antibody can accurately and efficiently detect
prostate cancer with reference to the current monoclonal antibody, this design promises to
revolutionize prostate cancer diagnostics.

Future Work
In order to replace current diagnostic techniques with this newly engineered synthetic
antibody, future work must be done to ensure that non-specific binding does not affect
measurements of PSA concentrations. This will be done through various assays which will
test the synthetic antibodies tendencies to bind to various molecules or surfaces. Issues
caused by non-specific binding can also be ameliorated by introducing various constraints
which will allow a signal to be emitted only when the synthetic antibody is bound to PSA.

Future Applications
Both the unnatural amino acid incorporation and synthetic antibody designs present models
which can be used for a variety of medical and research applications. Unnatural amino acid
incorporation is a promising new technology; by introducing non-biologically relevant amino
acids into protein sequences, engineers are effectively expanding the genetic code. As shown
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by L-DOPA’s ability to greatly increase bond strength, expansion of the genetic code through
this method introduces novel functions into the biological world. The synthetic antibody
model can also be replicated for countless applications. By replacing monoclonal antibodies
produced by the hybridoma model, these E. Coli based synthetic antibodies can ameliorate
ethical concerns regarding animal welfare and accessibility in research and medical
applications.
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Chapter 5: Ethical Concerns
Traditional monoclonal antibody production is a well known process that has been used to
create antibodies that have high specificity and binding strength. While these traditional
production techniques are highly effective, they carry with them two main ethical concerns
that synthetic antibodies work to address. The first concern centers around animal welfare, as
the production process requires the antibodies to be produced in vivo. The second concern is
the related expenses associated with the current production techniques that have contributed
to the extremely high cost of traditional monoclonal antibody therapies.

Animals are required for the current production of monoclonal antibodies. While their
treatment during incubation may be up to current ethical standards, much debate exists
around the extraction process. Prior to harvesting monoclonal antibodies, the immune
systems of the animals must be stimulated with a particular disease agent to saturate the
blood with antibodies. This practice is life-threatening, incurring a high high mortality rate,
and as such, creates a extensive ethical dilemma for the scientists and companies that employ
it. As an alternative, synthetic antibodies are manufactured in E. Coli which removes the
animal from the production cycle entirely, thereby eliminating the ethical dilemma
surrounding production.

The use of animals for production also contributes to the extremely high costs associated
with traditional monoclonal antibody production. These high costs severely limit access to
these antibodies to only the select few who can pay the high price. These antibodies are an
incredibly useful tool for researchers and doctors alike, but due to high costs, many
institutions and research centers shy away from them. This creates the ethical dilemma
because many people could be helped by this technology, but due to its high cost, very few
people can afford to work with or utilize them, severely limiting the scope of research on the
subject. With synthetic antibodies, the production systems have been validated through
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literature and practice as being low cost, high quality systems. This would dramatically
reduce the cost of monoclonal antibodies, allowing for an increase in the scope of research
and usage.
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Chapter 6: Engineering Standards and
Realistic Constraints
Purpose
Engineering design requires that certain considerations be taken into account before the
design process begins. The following factors will be discussed using a framework that
analyzes the impact each factor has on the project and its stakeholders.

Economic
Despite this being a project and product focused on saving lives, the economic factors of this
project must be taken into account when considering the realistic constraints of this project.
The budget for this project takes into account the funding required to fully carry out all of the
experiments. The economic advantages of designed synthetic antibodies are apparent when
discussing large scale antibody production. Traditional antibody production requires large
investments in resources and animal care facilities to make production viable, but the
extensive costs associated with these resources and facilities are eventually passed on to the
patient in the form of high drug costs. Synthetic antibody production, on the other hand, is
done in E. Coli, which both reduces the cost of small scale testing and makes production
easily scalable, significantly reducing the costs and resources necessary for production. This
makes the synthetic antibody proposed in this paper a less expensive alternative to traditional
monoclonal antibodies, allowing for greater patient access.

Ethical
There are two main analyses that must be conducted from an ethical standpoint for this
project. The first is to perform a stakeholder analysis. Stakeholders for this project include
the producers of the synthetic antibody, intermediate users of the antibody such as
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researchers, industry experts and scientists, and academic institutions, and finally the end
users of the synthetic antibody as patients and those who would be both directly and
indirectly impacted by the use of the antibodies. The next, and far broader analysis is one that
involves addressing the ethical concerns, dilemmas, and benefits of these synthetic
antibodies. The largest benefits of synthetic antibody production come from the cost savings
associated with a leaner production cycle, and the elimination of animal usage during
production. These benefits eliminate the two largest ethical concerns for traditional
monoclonal antibody production.

One of the largest ethical concerns associated with synthetic antibody production is the
concern of the possibility of using all parts of the process in the production of biological
weapons. Screening methods can be repurposed to identify peptides that cause disease or
physiological disorders. These peptides could then be manufactured using the production
methods outlined in this paper to produce a bioweapon either in a small, unregulated facility
or on a large scale for a very low cost. This ethical concern should be understood and
addressed, but the utilization of the techniques described in this paper to produce a
bioweapon requires extensive and intimate knowledge of multiple disciplines. This
knowledge requirement significantly reduces the risk of exploitation of the manufacturing
methods identified in this paper; however, engineering ethical standards should be
maintained so as not to cause harm to any of the stakeholders or other members of society
identified in this section.

Social
As this project has health and medical implications, social responsibility as it relates to every
stakeholder identified must be taken into consideration. The current high cost of monoclonal
antibodies prevents those stakeholders who do not have the financial means to afford
antibody treatment from seeking antibody treatment, as insurance companies continue to
refuse to pay the incredibly high costs. Reducing the overall cost of antibody treatments
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through the introduction of synthetic antibody production would open up access to previously
expensive treatment regimens to a much larger portion of stakeholders than ever before.

Manufacturability
This project aimed to validate the manufacturing process outlined in this paper on a small
scale, with the notion that successes at this scale could be applied to a industrial scale
manufacturing. However, it is to be understood that small scale success does not imply that
the jump to production will be simple. There are several challenges and complications that
arise when attempting to scale up monoclonal antibody production. In the traditional
manufacturing methods, the largest problem is scaling up the animal production facilities
while maintaining the proper level of quality control in the produced antibodies. For
synthetic antibody manufacturing, this quality control challenge is all but eliminated through
the use of E. Coli as the production platform. Large scale bioreactor production of E. Coli
has been thoroughly documented in literature, and has been proven in practice in various
industrial settings. These previous successes significantly improve the possibility of a
successful scale-up of the manufacturing procedures verified through this project.

Health and Safety
Ensuring the health and safety of all stakeholders involved in the project is of the utmost
importance at all phases of the product. For the small scale production detailed in this paper,
all team members passed the Santa Clara University Laboratory Safety Protocol and
Procedures exam. This ensured the execution of the manufacturing plan in a proper lab
setting where all risks associated with the materials and procedures used in this project were
minimized. Members also had previous lab experience performing various laboratory
procedures, and as such were well trained in the handling of hazardous materials.

To protect the health and safety of the stakeholders undergoing treatments using these
synthetic antibodies, it is paramount that these antibodies only be used for their intended
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purpose. In the case of the project described in this paper, the specific antibody being
developed has the sole purpose of detecting the PSA biomarker. As such, the synthetic
antibody outlined in this paper should not be used to detect other biomarkers possibly present
in stakeholders undergoing treatment. Adherence to this principle will help ensure the health
and safety of those undergoing treatment.
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Appendix
Appendix A. pAC DHPheRS-6TRN plasmid map
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Appendix B. pET28b-P1+TAG+GFP+His plasmid map
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Appendix C. Synthetic Antibody Design
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Appendix D. Unnatural Amino Acid Incorporation Schematic
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Appendix E. L-DOPA Incorporation
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Appendix F. PSA Binding to Synthetic Antibody Schematic
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Appendix G. Hybridoma Model
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Appendix H. PageRuler Unstained Protein Ladder
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Appendix I. L-DOPA and Tyrosine Structures
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